Praful Ravi

15PUBLICATIONS
52CO-AUTHORS
Predictive and prognostic markersRadiation therapyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 23, 2026
Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high-risk prostate cancer: A predictive biomarker analysis.

|Apr 24, 2026
Efficacy and Safety of 177Lu-PSMA-617 in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer.

|Jan 15, 2026
Current and future perspectives on radioligand therapy in advanced prostate cancer.

Buraq Ahmed, Praful Ravi

|Jan 12, 2026
Integrative Clinical and Molecular Evaluation of Renal Cell Carcinoma with Merlin Protein Deficiency and Biallelic Loss of NF2.

Emre Yekedüz, Weiwei Bian, Stephanie E Siegmund

|Mar 19, 2025
Outcome of Subsequent Therapies After 177Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience.

Meryam Losee, Michael Kavanaugh, Mofei Liu

|Jan 08, 2025
Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer.

Praful Ravi, Wanling Xie, Silke Gillessen

Pageof 3

Frequent Collaborators

2 joint publications

Daniel S Childs

2 joint publications

Heather Jacene

2 joint publications

Atish D Choudhury

2 joint publications

Anthony V D'Amico